RESEARCH ARTICLE

CircRNA ARFGEF1 functions as a ceRNA to promote oncogenic KSHV-encoded viral interferon regulatory factor induction of cell invasion and angiogenesis by upregulating glutaredoxin 3

Shuihong Yao1,2,3*, Xuemei Jia4*, Fei Wang2, Liuxue Sheng2, Pengxia Song3, Yanhui Cao5, Hongjuan Shi3, Weifei Fan5*, Xiangya Ding4*, Shou-Jiang Gao6, Chun Lu1,2,4,5*

1 Key Laboratory of Pathogen Biology of Jiangsu Province, Nanjing Medical University, Nanjing, P. R. China, 2 Department of Microbiology, Nanjing Medical University, Nanjing, P. R. China, 3 Medical School, Quzhou College of Technology, Quzhou, P. R. China, 4 State Key Laboratory of Reproductive Medicine, Department of Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Hospital, Nanjing Medical University, Nanjing, P. R. China, 5 Department of Hematology and Oncology, Department of Geriatric Lung Cancer Research Laboratory, Geriatric Hospital of Nanjing Medical University, Nanjing, P. R. China, 6 UPMC Hillman Cancer Center, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

* These authors contributed equally to this work.

Abstract

Circular RNAs (circRNAs) are novel single-stranded noncoding RNAs that can decoy other RNAs to inhibit their functions. Kaposi’s sarcoma (KS), caused by oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV), is a highly angiogenic and invasive vascular tumor of endothelial origin commonly found in AIDS patients. We have recently shown that KSHV-encoded viral interferon regulatory factor 1 (vIRF1) induces cell invasion, angiogenesis and cellular transformation; however, the role of circRNAs is largely unknown in the context of KSHV vIRF1. Herein, transcriptome analysis identified 22 differentially expressed cellular circRNAs regulated by vIRF1 in an endothelial cell line. Among them, circARFGEF1 was the highest upregulated circRNA. Mechanistically, vIRF1 induced circARFGEF1 transcription by binding to transcription factor lymphoid enhancer binding factor 1 (Lef1). Importantly, upregulation of circARFGEF1 was required for vIRF1-induced cell motility, proliferation and in vivo angiogenesis. circARFGEF1 functioned as a competing endogenous RNAs (ceRNAs) by binding to and inducing degradation of miR-125a-3p. Mass spectrometry analysis demonstrated that glutaredoxin 3 (GLRX3) was a direct target of miR-125a-3p. Knockdown of GLRX3 impaired cell motility, proliferation and angiogenesis induced by vIRF1. Taken together, vIRF1 transcriptionally activates circARFGEF1, potentially by binding to Lef1, to promote cell oncogenic phenotypes via inhibiting miR-125a-3p and inducing GLRX3. These findings define a novel mechanism responsible for vIRF1-induced oncogenesis and establish the scientific basis for targeting these molecules for treating KSHV-associated cancers.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), which frequently occurs in people with AIDS. We and others had proved that KSHV-encoded viral interferon regulatory factor 1 (vIRF1) was crucial in the pathogenesis of KSHV-induced cancers. KSHV genome transcribes viral circular RNAs (circRNAs), however, the role of cellular circRNAs in vIRF1-induced tumorigenesis remains unknown. CircRNAs serves as competitive endogenous RNAs (ceRNAs) of miRNAs, thus regulating miRNA-mRNA network to influence mRNA stability and protein expression. Here we found that vIRF1 binds to the promoter of the parental gene ARFGEF1 and activate circARFGEF1 transcription through interaction with transcription factor lymphoid enhancer binding factor 1 (Lef1). CircARFGEF1 functioned as a ceRNA by binding to and inducing degradation of miR-125a-3p, thereby abrogating the inhibition effect of this miRNA on its direct targeting of GLRX3. Significantly, circARFGEF1/miR-125a-3p/GLRX3 axis was required for vIRF1 induction of cell motility, proliferation and in vivo angiogenesis. In summary, our study describes a novel mechanism of KSHV-induced oncogenesis by hijacking host circRNAs through a viral oncogene.

Introduction

Kaposi’s sarcoma (KS), which arises in skin lesions, lymph nodes, mucous membranes and other organs, is the most common malignant tumor in patients with HIV/AIDS [1,2]. Skin KS is characterized by the abnormal angio-proliferative and metastasis of endothelium cells [2]. Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the etiological agent of KS [3]. Besides KS, KSHV also causes two B-cell lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD), and KSHV-associated inflammatory cytokine syndrome (KICS) [4].

Like other herpesviruses, KSHV contains two life cycles, lytic replication and latency [5]. KSHV encodes several oncoproteins, which are essential for the development and progression of KS [6]. Among them, viral interferon regulatory factor 1 (vIRF1) is encoded by open reading frame (ORF)-K9, which shares ~25% homology to human cellular IRFs [7]. vIRF1 is a lytic gene [8]. We and others detected the expression of vIRF1 protein and mRNA in KSHV-infected cells in KS tumors [9,10]. Regarding immune response, vIRF1 competitively binds to IRFs to inhibit their transcriptional activity and attenuates the expression of IFN-induced genes [11,12]. Nevertheless, vIRF1 is not limited to the anti-viral immune response. vIRF1 suppresses p53 function and TGF-β/Smad signaling, participating in cancer regulatory network [13,14]. In addition, vIRF1 plays a key role in KSHV lytic replication. vIRF1 directly binds to a mitophagy receptor, NIX, on the mitochondria and activates NIX-mediated mitophagy to promote mitochondrial clearance, resulting in enhanced KSHV productive replication [15]. Although we and others have shown that vIRF1 promotes cell migration, invasion, proliferation, angiogenesis, cellular transformation and tumorigenesis in vitro and in vivo [9,12,16,17], the underlying mechanisms of vIRF1-mediated tumor pathogenesis still remain to be explored.

Circular RNA (circRNA), a new class of non-coding RNAs, is a kind of covalently closed-loop RNA without 3’ and 5’ ends [18]. circRNAs are the products of mRNA alternating spicing, occurring in homo sapiens, mouse, C. elegans, Drosophila, yeast and plants [19–21]. Recently, human cellular circRNAs were reported to play an crucial role in the occurrence and
development of human diseases, especially in human cancers [22]. By RNA sequencing, KSHV was found to encode numerous back-spliced circRNAs including circvIRF4, circK7.3s and circcPANs [23–26]. These three circRNAs could be packed into KSHV particles. Similar to Orf-K7.3 and PAN, circK7.3s and circcPANs were induced upon KSHV lytic replication, and only circvIRF4 was constitutively expressed in KSHV infected cells [25,26]. Although cellular circRNAs regulated by KSHV had been identified in primary human umbilical vein endothelial cells (pri-HUVECs) and B cell line [24], whether cellular circRNAs were involved in KSHV vIRF1-induced tumorigenesis remains largely unknown.

To date, most studies demonstrate that cellular circRNAs function as competing endogenous RNAs (ceRNAs) to sponge miRNAs, resulting in the elevation of miRNAs targeted genes [19,27]. For example, circular RNA cESRP1 inhibited TGF-β pathway by sponging miR-93-5p to sensitize cells of small cell lung cancer to chemotherapy [28]. However, circRNAs are not limited to act as sponges for miRNAs. circRNA-protein interaction exhibits another possibility to regulate cellular process. For instance, circAGO2, a circRNA generated from AGO2 gene, directly interacts with HuR, which activates HuR to mediate AGO2/miRNA dependent gene silencing to drive cancer progression [28].

In this study, we aimed to unfold the role of vIRF1-regulated cellular circRNAs in the tumorigenesis of KS and the underlying mechanisms. We identified vIRF1-regulated circRNAs through RNA sequencing in endothelial cells infected by KSHV and a vIRF1 mutant virus. Six circRNAs increased by vIRF1 and 16 circRNAs decreased by vIRF1 were authenticated and analyzed by bioinformatics tools. Among them, hsa_circ_0001808, which was named circARFGEF1 in this study, is generated from the ARFGEF1 gene locus. vIRF1-activated circARFGEF1 transcription by interacting with transcription factor lymphoid enhancer binding factor 1 (Lef1). Furthermore, the decreased miR-125a-3p was sponged by circARFGEF1. Mass spectrometry analysis and luciferase reporter assay demonstrated that GLRX3 was a direct target of miR-125a-3p. More importantly, circARFGEF1/miR-125a-3p/GLRX3 axis was involved in vIRF1-induced cell motility, proliferation and in vivo angiogenesis. In conclusion, our results imply that vIRF1-modulated circARFGEF1/miR-125a-3p/GLRX3 axis is crucial for the pathogenesis of KSHV-induced tumors, which could be a potential molecular therapeutic target for treating KSHV-related diseases.

Results

Identification of KSHV vIRF1-regulated circRNAs by RNA-sequencing

To identify cellular circRNAs regulated by KSHV vIRF1, an endothelial cell line EA.hy926 was either treated with PBS, or infected with 3 MOI of KSHV_WT virus or vIRF1_mut virus for 3 days [16,17]. We characterized circRNAs profiles in these cells by total RNA-sequencing. Cluster analysis showed that cells infected by KSHV_WT had a circRNA expression pattern distinct from those infected by the vIRF1_mut virus (Fig 1A). The Volcano Plots revealed the differential distributions of circRNAs in KSHV_WT and vIRF1_mut virus-infected cells compared to those of PBS and KSHV groups, respectively (Fig 1B and 1C). There were 127 differentially expressed circRNAs in KSHV_WT virus-infected cells compared to the PBS group, and 163 differentially expressed circRNAs in KSHV_WT virus-infected cells compared to the vIRF1_mut virus-infected cells (Fig 1D and 1E). We identified 22 circRNAs including 6 vIRF1-upregulated and 16 vIRF1-downregulated circRNAs (Fig 1D and 1E). Clustering analysis showed that differential expression and sample quality of these 22 vIRF1-regulated circRNAs were reliable and stable (Fig 1F).

To examine the expression of vIRF1-regulated circRNAs, we first established ectopic vIRF1-expressing EA.hy926 cells by transduction with 2 MOI of lentiviral vIRF1. We found that...
at this MOI vIRF1-transduced cells showed a vIRF1 mRNA level similar to that of KSHV-infected cells (S1 Fig). The lentiviral vIRF1 was generated in our recent study [16]. RT-qPCR was performed to validate 6 vIRF1-upregulated circRNAs in RNA-sequencing. We found that at this MOI vIRF1-transduced cells showed a vIRF1 mRNA level similar to that of KSHV-infected cells (S1 Fig). The lentiviral vIRF1 was generated in our recent study [16]. RT-qPCR was performed to validate 6 vIRF1-upregulated circRNAs in RNA-sequencing. We found that
hsa_circ_0001808 was increased at the highest level in vIRF1-transduced cells compared to control lentiviral pHAGE (Fig 1G). According to the human reference genome, hsa_circ_0001808, which was located at chr8: 2966846–2983691, and derived from gene ARFGEF1, was termed as “circARFGEF1”.

vIRF1-Lef1 complex activates circARFGEF1 transcription to promote cell motility and angiogenesis

As annotated in circBase (www.circbase.org), circARFGEF1 arises from the ARFGEF1 gene and consists of the head-to-tail splicing of exon 2, 3 and 4 (335 nt) (Fig 2A, upper and middle panels). The back-splice junctions of circARFGEF1 were confirmed by Sanger sequencing (Fig 2A, lower panel). To verify the endogenous circARFGEF1 generated from the exons of ARFGEF1 gene, we designed divergent and convergent primers that specifically amplified the back-spliced and canonical form of ARFGEF1. With divergent primers, circARFGEF1 was amplified by RT-PCR from cDNA template but not gDNA (Fig 2B). Furthermore, circARFGEF1 rather than linear ARFGEF1 was resistant to RNase R digestion, which degrades linear RNAs but does not act on circular RNA (Fig 2C). Besides being increased in vIRF1-transduced cells (Figs 1G and 2D), circARFGEF1 was also induced in KSHV-infected cells (Fig 2E). To compare the expression between circARFGEF1 and linear ARFGEF1 or pre-mRNA of ARFGEF1, we generated specific primers that targeted the different RNA molecules. The results showed that pre-mRNA of ARFGEF1 was increased in both vIRF1-transduced and KSHV-infected cells, whereas KSHV or vIRF1 has no effect on linear ARFGEF1 (Figs 2D and 2E and S2). Consistent with these observations, neither vIRF1 transduction nor KSHV infection affected the protein level of ARFGEF1 in EA.hy926 cells (S3A and S3B Fig).

Like most circRNAs, circARFGEF1 is mostly localized to the cytoplasm (Fig 2F). To examine whether vIRF1 regulates the transcription of circARFGEF1, we performed a dual-luciferase reporter gene assay. We found that vIRF1 activated circARFGEF1 promoter activity (Fig 2G). Our recent studies reported that vIRF1 interacted with transcription factor Lef1 to bind to the promoters of CDCP1 and SPAG9 genes, and enhance their transcriptions and expressions [9,17]. Here, we first overexpressed Lef1, and found that circARFGEF1 transcription was significantly enhanced by Lef1 (Fig 2H). Knockdown of the Lef1 with a mixture of lentivirus-mediated short hairpin RNAs (shRNAs) targeting Lef1 dramatically impaired the activation of effect of vIRF1 on the circARFGEF1 promoter in a luciferase reporter assay (Fig 2I). To confirm the physical interaction of Lef1 with the sequence of circARFGEF1 promoter, the chromatin immunoprecipitation assay (ChIP) was performed. We observed that binding of Lef1 to circARFGEF1 promoter was increased in the presence of vIRF1 (Fig 2J).

Our recent reports showed that vIRF1 promoted endothelial cell migration, invasion, proliferation, angiogenesis and cellular transformation [9,16,17]. We asked whether vIRF1-upregulated circARFGEF1 was involved in this process. To exclude the effect of the parental gene ARFGEF1 of circARFGEF1 on these cell malignant phenotypes, we examined ARFGEF1 expression after lentivirus-mediated overexpression or knockdown of circARFGEF1. We found that either overexpression or silencing of circARFGEF1 didn’t affect the mRNA level of its parental gene ARFGEF1 (S4 and S5 Figs). Loss of circARFGEF1 significantly inhibited vIRF1-induced endothelial cell migration and invasion (Figs 3A–3C and S6). Similarly, knockdown of circARFGEF1 impeded vIRF1-induced cell proliferation in a plate colony formation assay (Fig 3D and 3E), while the inhibitory effect on the plate colony formation by silencing of circARFGEF1 was reversed by overexpression of circARFGEF1 in EA.hy926 cells (S7 Fig).
examine the effect of circARFGEF1 on in vivo angiogenesis, matrigel plug assay in mice was performed. Knockdown of circARFGEF1 impaired vIRF1-induced angiogenesis (Fig 3F and 3G). Taken together, these data suggest that vIRF1-Lef1 complex enhances circARFGEF1 transcription to promote vIRF1-induced cell motility, proliferation and angiogenesis.
Fig 3. circARFGEF1 promotes vIRF1-induced cell motility, proliferation and angiogenesis. (A) RT-qPCR analysis of circARFGEF1 expression in vIRF1-expressing EA.hy926 cells transduced with a mixture of shRNAs targeting circARFGEF1 (shcircARFGEF1 mix). (B) Migration analysis of pri-HUVECs treated as in (A). Transwell migration assay was performed as described in the "Materials and methods" section. (C) Invasion analysis of pri-HUVECs treated as in (A). Transwell invasion assay was performed as described in the "Materials and methods" section. (D) Plate colony formation assay of endothelial cell line EA.hy926 treated as in (A). Plate colony formation assay was performed as described in the "Materials and methods" section. (E) Quantification of cell colony formation described in (D). (F) The mixture containing high concentration Matrigel and endothelial cell line EA.hy926 treated as in (A) was injected into nude mice. Representative photographs of plugs were exhibited. Scar bars, 1 cm. (G) The level of hemoglobin in plug tissues treated in (F) was measured by comparing the standard curve. Data were shown as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001, n.s, not significant. Statistical significance was determined using one-way ANOVA followed by Tukey's multiple comparisons test.

https://doi.org/10.1371/journal.ppat.1009294.g003
circARFGEF1 binds to and degrades miR-125a-3p to promote vIRF1-induced cell invasion and angiogenesis

CircRNAs are known to function as competitive endogenous RNAs (ceRNAs) to sponge miRNAs [29]. To identify the miRNA(s) that involved in the vIRF1-circARFGEF1 network, we analyzed our previous miRNA data generated from vIRF1-transduced cells (GEO accession number: GSE119034) [16]. The Basic Local Alignment Search Tool (BLAST) was used to predict potential binding between circARFGEF1 and vIRF1-downregulated miRNAs. As a result, there were five miRNAs, which exhibited the potential binding to circARFGEF1 (Fig 4A). To validate the interaction between miRNAs and circARFGEF1, we constructed a reporter plasmid, where the circARFGEF1 sequence was cloned into the downstream of luciferase gene in the pGL3-control plasmid, and co-transfected the reporter plasmid with each of the five miRNA mimics into 293T cells, respectively. A dual luciferase reporter system was performed to validate the binding of miRNA and circARFGEF1. It was showed that only miR-125a-3p reduced circARFGEF1 luciferase activity (Fig 4B). RT-qPCR indicated that miR-125a-3p was decreased in both vIRF1-transduced and KSHV-infected EA.hy926 cells (Fig 4C and 4D). The extents of miR-125a-3p reduction detected by microarray and qPCR methods varied, which could be due to the nature of the two different methods; however, they were in the same scale. miR-125a-3p inhibited circARFGEF1 luciferase activity in a dose-dependent manner in a luciferase reporter assay (Fig 4E and 4F). To examine the binding site located in circARFGEF1 sequence, we generated the mutated miR-125a-3p according to the sequences of putative binding site (Fig 4G). miR-125a-3p mutation on the seed sequence failed to inhibit the circARFGEF1 reporter activity (Fig 4H). To determine whether the interaction between circARFGEF1 and miR-125a-3p existed in cells, we generated biotin-labeled wild type (WT) of miR-125a-3p and mutated miR-125a-3p. Biotin-coupled RNA pull-down assay showed that circARFGEF1 was enriched in miR-125a-3p WT group but not in mutated group (Fig 4I). We further examined the expression level of miR-125a-3p following overexpression of circARFGEF1 (1 MOI) at a level comparable that of KSHV-infected EA.hy926 cells (Figs 4J and S4A). We found that the level of miR-125a-3p was dramatically decreased after overexpression of circARFGEF1 (Fig 4K). More importantly, miR-125a-3p was degraded in circARFGEF1-expressing cells in response to actinomycin D (Fig 4L). Collectively, these data suggest that circARFGEF1 served as a sponge of miR-125a-3p, inducing its degradation.

Next, we examined the effect of miR-125a-3p on vIRF1 induction of cell motility and angiogenesis. We found that overexpression of miR-125a-3p in vIRF1-transduced cells had an inhibitory effect on vIRF1-induced cell migration and invasion (Fig 5A–5C). Consistently, overexpression of miR-125a-3p impeded vIRF1-induced cell proliferation in a plate colony formation assay (Fig 5D and 5E). More importantly, induction of miR-125a-3p impaired vIRF1-enhanced angiogenesis in vivo based on a matrigel plug assay in mice (Fig 5F and 5G). Together these data suggest that circARFGEF1 binds to and degrades miR-125a-3p to promote vIRF1-induced cell invasion, proliferation and angiogenesis.

miR-125a-3p directly targets GLRX3 to negatively regulate vIRF1-induced cell invasion and angiogenesis

To identify the targets of miR-125a-3p, we examined proteins differential expressed between vIRF1- and pHAGE-transduced cells by mass spectrometry analysis (S1 Table). Bioinformatics analysis with several programs predicted the putative miR-125a-3p targets in vIRF1-upregulated proteins. As shown in Fig 6A, we predicted 7 proteins that might have miR-125a-3p putative binding sites in their CDS or 3′ UTR. A luciferase reporter assay confirmed that only miR-125a-3p significantly decreased the luciferase activity of the 3′ UTR reporter of glutaredoxin 3
KSHV vIRF1 hijacks circRNA to promote angiogenesis
between miR-125a-3p and GLRX3 3'UTR, a miR-125a-3p mutant was generated based on changed in a dose-dependent pattern (Figs 6F, 6G and S8). To identify the interacting site with increasing amounts of miR-125a-3p mimics or inhibitors, GLRX3 protein expression was determined by Western blotting. (B) BLAST prediction (Fig 6H). Mutation in seed sequence of miR-125a-3p dramatically eliminated the inhibitory effect of miR-125a-3p on GLRX3 expression (Fig 6I and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing and miRNA-mediated post-transcriptional gene silencing (ceRNA) to abolish the function of miR-125a-3p by releasing its targets from Ago2-RISC. [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolish the function of miR-125a-3p on GLRX3 expression (Fig 6L and 6J). Since Ago2 is a component of RNA-induced silencing complexes (RISC) which induce mRNA silencing [30], we employed Ago2-RIP assay to examine whether circARFGEF1 acts as competitive RNA (ceRNA) to abolis...
Fig 5. Overexpression of miR-125a-3p inhibits vIRF1-induced cell motility, proliferation and angiogenesis. (A). Transwell migration (top) and Matrigel invasion (bottom) assays for pri-HUVECs transduced with lentiviral vIRF1 or its control pHAGE, which were subsequently co-transduced with lentivirus-miR-125a-3p (miR-125a-3p) and its control mpCDH. The representative images were captured at 6 and 12 h post seeding (original magnification, ×100). (B). The quantification results of Transwell migration assay in (A).
phenotypes (Figs 7H–7K and S10). These data collectively suggest that miR-125a-3p directly targets GLRX3 to negatively regulate vIRF1-induced cell invasion, proliferation and angiogenesis.

vIRF-circARFGEF1/miR-125a-3p/GLRX3 axis is essential for KSHV-induced cell invasion and angiogenesis

To determine the role of circARFGEF1/miR-125a-3p/GLRX3 axis in vIRF1-induced cell invasion and angiogenesis in the presence of KSHV genome, we employed a KSHV mutant virus with deleted ORF-K9 to infect cells [16]. We have previously shown that deletion of vIRF1 from KSHV genome not only decreased KSHV-induced cell migration and invasion [16], but also lowered KSHV-induced angiogenesis and cellular transformation [9,17]. Here, we found that deletion of vIRF1 abolished the ability of KSHV-induced cell proliferation in a plate colony formation assay; however, complementation with a vIRF1 construct in the vIRF1_mut virus infected cells recovered this phenomenon (Fig 8A). Further, deletion of vIRF1 attenuated mRNA levels of circARFGEF1 and GLRX3, while complementation with the vIRF1 construct rescued their transcript levels (Fig 8B). Correspondingly, the mRNA level of miR-125a-3p had an inverse change compared to those of circARFGEF1 and GLRX3 mRNA (Fig 8B). Consistent with these observations, deletion of vIRF1 decreased GLRX3 protein level, which were completely reversed following vIRF1 complementation (Fig 8C). Additionally, silencing of circARFGEF1 in KSHV-infected cells not only reduced the ability of KSHV-induced cell proliferation in a plate colony formation assay (Figs 8D and S11A), but also resulted in increased miR-125a-3p and decreased GRLX3 (Fig 8E and 8F). Furthermore, knockdown of GLRX3 in KSHV-infected cells decreased their efficiency of plate colony formation (Figs 8G and S11B). Meanwhile, silencing of circARFGEF1 in vIRF1-transduced cells exhibited the similar results (Fig 8H and 8I). Collectively, these data indicate that by hijacking circARFGEF1 to function as a ceRNA, vIRF1 enhances cell motility, proliferation and angiogenesis by downregulating miR-125a-3p and releasing its target GLRX3.

Discussion

Although KSHV vIRF1 was characterized as a lytic protein [8,11], low level of vIRF1 expression was detected in KSHV-infected cells in KS tumors and PEL cells [10,31,32], suggesting that its expression in tumors could have occurred in a subset of lytically infected cells. In fact, about 1–3% of the KSHV-infected cells in KS tumors express viral lytic proteins [33–36]. The low rate of spontaneous lytic replication is presumed to produce infectious virions to infect new cells. Both the low rate of spontaneous lytic replication and de novo infection of new cells with infectious virions contribute to KSHV-induced pathogenesis, including that KSHV onco- genic proteins drive cell invasion, angiogenesis, and cellular transformation. On the other hand, both virus-encoded cytokines and cellular cytokines, growth factors and other cellular proteins induced during the low rate of spontaneous lytic replication and de novo infection of new cells by infectious virions promote KS pathogenesis through autocrine and paracrine mechanisms. Consistently, our most recent study reported that vIRF1-positive cells could be observed in KS lesions, indicating that the expression of vIRF1 protein is most likely due to viral lytic replication [9]. Thus, vIRF1 expression in tumors reinforces its critical role in KS.
miR-125a-3p directly targets GLRX3. (A) Heatmap analyses of mass spectrometry showing vIRF1 upregulated proteins that were predicted to be the targets of miR-125a-3p. (B) miR-125a-3p mimic (miR-125a-3p, 20 nM) or its control (Neg. Ctrl.) were co-transfected into HEK293T cells with reporter plasmids for 48 h and then were used for luciferase activity. (C) Western blotting of GLRX3 expression in EA.hy926 cells transfected with miR-125a-3p mimic (20 nM). (D) Luciferase activity in HEK293T cells co-transfected with miR-125a-3p mimic (miR-125a-3p; 20 nM) or its control (Neg. Ctrl.) and the reporter construct GLRX3_3'UTR or its control reporter construct pGL3_Ctrl for 48 h. (E) Luciferase activity in HEK293T cells co-transfected with increasing amounts of miR-125a-3p mimic (miR-125a-3p; 10, 20, and 50 nM) or its control (Neg. Ctrl.), and the reporter construct GLRX3_3'UTR for 48 h. (F) Western blotting of GLRX3 expression in EA.hy926 cells transfected with increasing amounts of miR-125a-3p mimic (10, 20 and 50 nM) or its control (Neg. Ctrl.) for 48 h. (G) Western blotting of GLRX3 expression in EA.hy926 cells transfected with increasing amounts of miR-125a-3p inhibitor (10, 20 and 50 nM) or its control (Neg. Ctrl.) for 48 h. (H) Putative binding site of miR-125a-3p in the 3'UTR region of GLRX3 and mutagenesis of target site in miR-125a-3p (miR-125a-3p mut 2). (I) Luciferase activity in HEK293T cells co-transfected with miR-125a-3p mimic (20 nM), miR-125a-3p mutant 2 mimic (20 nM) or a negative control (Neg. Ctrl.) and the GLRX3_3'UTR reporter construct for 48 h. (J) Western blotting of GLRX3 expression in EA.hy926 cells transfected with miR-125a-3p mimic (20 nM), miR-125a-3p mutant 2 mimic (20 nM) or a negative control (Neg. Ctrl.) for 48 h. (K) RIP results in EA.hy926 cells showing the enrichment of binding of circARFGEF1, GLRX3 mRNA with miR-125a-3p based on Ago2 immunoprecipitation assay. Data were shown as mean ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001; n.s, not significant. Statistical significance was determined using Student’s t-test in B and K; one-way ANOVA followed by Tukey’s multiple comparisons test in D and I.

https://doi.org/10.1371/journal.ppat.1009294.g006

tumorigenesis. It has been shown that vIRF1 shares significant homology with cellular IRF-4, -8, -9 at the DNA binding domain (DBD) [37]. The crystal structure of the vIRF1 DBD also supports that vIRF1 is a DNA-binding protein [38]. Consistent with these findings, vIRF1 was found to locate in the promoters of KSHV ORF-K3, vDHFR and vIL-6, resulting in the induction of these genes [39]. Here, we firstly reported the vIRF1 binding to the promoter of cellular gene ARFGEF1 to activate its transcription through interaction with the transcriptional factor Lef1. Despite more pre-mRNA of ARFGEF1 was generated after ARFGEF1 transcription activation, the mRNA and protein levels of ARFGEF1 did not change, while circARFGEF1 was significantly increased in vIRF1-transduced cells and KSHV infected cells. It is possible that this is due to the competition between canonical pre-mRNA splicing and circularization of exons [40]. This led us to speculate that some circRNA-related splicing factors might be dysregulated by vIRF1 and KSHV, resulting in more circARFGER1 production rather than ARFGEF1. Therefore, these elusive molecules and mechanisms remain to be further explored.

Currently, mounting evidence indicates that circRNAs play indispensable roles in various diseases, especially in cancers [41]. Surprisingly, KSHV itself makes multiple circRNAs (circ-vIRF4, circK7.3s and circPANs) [23]. Circ-vIRF4 was highly expressed in BCBL-1 cells but was lowly expressed in BC1 cells [25], indicating the distinct circRNAs expression patterns in the different cells. Cytoplasmic circ-vIRF4 was a component of KSHV viral particles, and circPANs was associated with viral life cycle [25]. Besides circ-vIRF4 and circPANs, many other KSHV circRNAs were detected by circRNAs sequencing in BCBL-1 and BC1 cells [23]. Similarly, using primary human umbilical vein endothelial cells (pri-HUVECs) or a B cell line (MC116, KSHV negative), the cellular circRNAs profile was examined upon de novo infection with KSHV for 6 h using circRNA microarray [24]. A total of 264 and 285 dysregulated circRNAs were identified in KSHV-infected pri-HUVECs and MC116 cells, respectively, but only 7 of the same circRNAs were dysregulated in both cell types [24]. In the current study, we established the profile of circRNAs in KSHV-infected EA.hy926 cell line, which was generated by fusing primary human umbilical vein endothelial cells with a thioguanine-resistant clone of AS49 (a human lung carcinoma cell line) in the presence of polyethylene glycol (PEG), and the hybrid clones were subsequently selected in hypoxanthine-aminopterin-thymidine (HAT) medium and screened for factor VIII-related antigen. We had compared our results to those of pri-HUVECs, however, we found only one circRNA that was dysregulated in both two cells. We speculated that this is probably due to the genetic heterogeneity and different methods of KSHV infection in these two types of cells. This scenario is similar to the differences of circRNAs between KSHV-infected pri-HUVECs and MC116 [24]. Although KSHV-regulated cellular circRNAs have been identified and KSHV decreased hsa_circ_0001400 regulates the expression of KSHV genes (LANA and RTA) and cell growth [24], vIRF1-regulated cellular
GLRX3 promotes vIRF1-induced cell motility, proliferation and angiogenesis. (A) RT-qPCR analysis of GLRX3 mRNA level in vIRF1-transduced EA.hy926 cells or its control pHAGE-transduced cells. (B) Western blotting analysis of GLRX3 protein level in vIRF1-transduced EA.hy926 cells or its control pHAGE-transduced cells. (C) RT-qPCR analysis of GLRX3 mRNA level in KSHV (3 MOI) infected EA.hy926 cells or its control PBS-treated cells. (D).
circRNAs remains unclear. Here we identified circARFGEF1 as a circRNA upregulated in both vIRF1-transduced and KSHV-infected cells. Mechanistically, vIRF1 enhanced circARFGEF1 transcription, potentially by forming a complex with transcription factor Lef1, resulting in cell migration, invasion, proliferation, and in vivo angiogenesis. circARFGEF1 was the first reported circRNA regulated by a KSHV gene and it mediated KSHV induction of oncogenic phenotypes. Of course, our results did not exclude the possibility that other KSHV genes could also regulate circRNAs and that vIRF1 might also regulate other circRNAs involved in KSHV-induced oncogenesis.

To search for the downstream miRNAs regulated by circARFGEF1, we re-analyzed our previous data of vIRF1-regulated miRNA array [16]. miR-125a-3p, which was generated from hsa-miR-125a Stem-loop sequence (Accession ID: MI0000469), was a down-regulated miRNA in both vIRF1-transduced and KSHV-infected cells. miR-125a-3p exhibits a tumor suppressive function in most tumors, such as gliomas, hepatocellular carcinoma, renal cell carcinoma and ovarian carcinoma [42–45]. Similar to miR-125a-3p, miR-125a-5p was decreased in gliomas, breast cancer, lung adenocarcinoma and ovarian cancer [46–49]. In contrast, miR-125a-3p was significantly up-regulated in early lung adenocarcinomas [50]. miR-125a-3p inhibited renal cell angiogenesis by targeting VEGF [44]. In gliomas, circ-MAPK4 inhibited cell apoptosis and promoted cell proliferation via activating p38/MAPK signaling by sponging miR-125a-3p in gliomas [42]. In addition, IncRNA MALAT1 modulated miR-125a-3p to increase FOXM1 expression, resulting in hepatocellular carcinoma progression [43]. Similar to most tumors, in this study, our results also indicated a tumor suppressive function of miR-125a-3p. miR-125a-3p was decreased in both KSHV-infected cells and vIRF1-transduced cells, and overexpression of miR-125a-3p reversed vIRF1-induced oncogenic phenotypes. Furthermore, circARFGEF1 served as a sponge and bound to miR-125a-3p resulting in its decreased stability. One mechanism that mediates destabilization of miRNAs is through RNA-directed miRNA degradation (TDMD). Artificial targets with extensive complementarity to the miRNA can trigger TDMD through a poorly understood process associated with tailing (addition of untemplated nucleotides) and trimming of the miRNA 3′ terminus [51,52]. However, whether vIRF1 decreases miR-125a-3p level through its precursor is still unknown.

Although GLRX3, also known as protein kinase C-interacting cousin of thioredoxin (PIOCT), has been identified for almost two decades, its biological function remains largely unclear. GLRX3 was recently reported to bind to polycomb group (PcG) proteins resulting in enhanced methylation of PcG target gene promoter [53,54]. Moreover, GLRX3 was an important factor for regulating stress-induced DNA-damage response. In oral squamous cell carcinoma, upregulated GLRX3 promoted cell migration and invasion through the Notch signaling
Fig 8. Loss of vIRF1 gene from KSHV genome reverses the tendency of circARFGEF1/miR-125a-3p/GLRX3 axis regulated by KSHV. (A). Plate colony formation analysis of EA.hy926 cells treated with PBS (PBS), infected with KSHV wild type virus (KSHV_WT; 3 MOI), vIRF1 mutant virus (vIRF1_mut), or vIRF1 mutant virus followed by transduction with lentiviral vIRF1 at MOI 2. (B). RT-qPCR analysis of levels of circARFGEF1, miR-125a-3p and GLRX3 mRNA in cells treated as in (A). (C). Western blotting analysis of GLRX3 protein in cells treated as in (A). (D). Plate colony formation analysis of EA.hy926 cells treated with PBS (PBS), infected with KSHV wild type virus (3 MOI) or transduced with lentivirus-mediated shcircARFGEF1 sequence targeting circARFGEF1. (E). RT-qPCR analysis of levels of miR-125a-3p and GLRX3 mRNA in KSHV (3 MOI) infected EA.hy926 cells transduced with lentivirus-mediated shcircARFGEF1 or its control mpCDH. (F). Western blotting analysis of the level of GLRX3 protein in cells treated as in (E). (G). Plate colony formation analysis of EA.hy926 cells treated with PBS (PBS), infected with KSHV wild type virus (3 MOI) or transduced with lentivirus-mediated shcircARFGEF1 sequence targeting circARFGEF1. (H). RT-qPCR analysis of levels of miR-125a-3p and GLRX3 mRNA in KSHV (3 MOI) infected EA.hy926 cells transduced with lentivirus-mediated shcircARFGEF1 or its control mpCDH. (I). Western blotting analysis of the level of GLRX3 protein in cells treated as in (E).
In this study, we have identified GLRX3 as a direct target of miR-125a-3p. GLRX3 was increased in vIRF1-transduced cells, KSHV-infected cells, and KS lesions. Knockdown of GLRX3 reversed vIRF1-induced cell motility, proliferation and *in vivo* angiogenesis, indicating that it has the characteristics of tumor genes. However, how GLRX3 promotes vIRF1-induced cell motility, proliferation and angiogenesis remains to be further explored.

In this study, we focused on the mechanism by which vIRF1 participates in KSHV-induced tumorigenesis by regulating cellular noncoding RNA. vIRF1 transcriptionally activates circARFGEF1 through interacting with Lef1, leading to the instability of miR-125a-3p, and increasing of GLRX3 (Fig 9). Our novel findings shed light on the regulatory network of cellular circRNA and its downstream pathway involved in KS pathogenesis, providing potential therapeutic targets of KSHV-induced cancers. This work also points to a new direction for understanding and exploring the pathogenesis of cancers induced by oncogenic viruses.

MOI) or transduced with lentivirus-mediated shGLRX3 targeting GLRX3. (H) RT-qPCR analysis of levels of miR-125a-3p and GLRX3 mRNA in vIRF1-expressing EA.hy926 cells transduced with lentivirus-mediated shcircARFGEF1 or its control mpCDH. (I) Western blotting analysis of the level of GLRX3 protein in cells treated as in (H). Data were shown as mean ± SD, * P < 0.05, ** P < 0.01, and *** P < 0.001, n.s, not significant. Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparisons test.

https://doi.org/10.1371/journal.ppat.1009294.g008

Fig 9. A hypothetical model of the mechanism of how vIRF1 regulates circARFGEF1/miR-125a-3p/GLRX3 axis. vIRF1 transcriptionally activates circARFGEF1 through interacting with Lef1, leading to the instability of miR-125a-3p, and increasing of GLRX3. Upregulation of GLRX3 protein promotes vIRF1 induction of cell migration, invasion and angiogenesis.

https://doi.org/10.1371/journal.ppat.1009294.g009
Materials and methods

Ethics statement
The KS clinical specimens were collected from the First Affiliated Hospital of Nanjing Medical University. The protocol was reviewed and ethically approved by the Institutional Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). Written informed consent was obtained from all anonymized adult participants.

Cells and transfection
iSLK-RGB-BAC16 and iSLK-RGB-K9 mutant cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 1 μg/ml puromycin, 250 μg/ml G418, and 1.2 mg/ml hygromycin B. Primary human umbilical vein endothelial cells (pri-HUVECs), which were used between passages 3 and 6, were isolated from the interior of the umbilical vein of human umbilical cords by digestion with collagenase (Sigma, St. Louis, MO, USA), and cultured in complete EBM-2 culture media (LONZA, Allendale, NJ, USA) as previously described [56]. pri-HUVECs were used for migration and invasion assays, a human umbilical vein endothelial cell line, EA.hy926 (catalog #CRL-2922; ATCC, Manassas, VA, USA) was employed for RNA-seq analysis, plate colony formation assay and in vivo matrigel plug assay, and HEK293T cells were used for lentivirus packaging and luciferase activity assay. Both HEK293T and EA.hy926 were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). All of cell lines were authenticated by short tandem repeat profiling. Effectence transfection reagent (Qiagen, Suzhou, Jiangsu, China) and Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA) were used for the transfection of endothelial cells and HEK293T cells, respectively.

Plasmids, lentivirus packaging and infection
The sequence of circARFGEF1 promoter was amplified from pri-HUVECs according Genecopoeia annotation and cloned into pGL3-basic plasmid (Promega, Shanghai, China). The pGL3-control vector was used to generate pGL3-circARFGEF1 and pGL3-GLRX3_3'UTR constructs by inserting the indicating sequences to the downstream of luciferase gene. The construct pGL3-circARFGEF1 contained full length of circARFGEF1 cDNA sequence, and pGL3-GLRX3_3'UTR included the full length of GLRX3 3'UTR sequence. Lef1 encoding sequences with HA tag at c-terminus were amplified by RT-PCR and cloned into pCDNA3.1 vector. The full-length of circARFGEF1 cDNA was amplified and cloned into the circRNA expression vector pLCDH-ciR (Geneseed Biotech Co, China), which contains front and back circular flanking sequences. microRNA mimics and related mimics control were got from GenePharma (Shanghai, China). The miR-125a-3p expressing plasmid was generated as previously described [16]. Briefly, lentiviral vector pCDH-CMV-MCS-EF1-copGFP was modified to contain miR-30 precursor stem-loops. Precursor stem-loops of miR-125a-3p was synthesized and cloned into modified pCDH (mpCDH). Similarly, short hairpin RNA (shRNA) expressing vectors were generated using mpCDH plasmid as previously described [57]. The shRNAs target the circARFGEF1 back-splice junction so as not to influence linear ARFGEF1. The shRNA sequences of circARFGEF1, Lef1 and GLRX3 were listed in S2 Table.

Lentivirus packaging and infection of target cells were performed as previously described [58]. Briefly, the packaging plasmid, psPAX2, together with the envelope plasmid, pMD2.G, and the recombinant lentivirus plasmids were co-transfected into pre-inoculated HEK293T cells. Lentivirus was collected and used to infect cells. The infection efficiency was monitored at 48 to 72 h post infection, and the infected cells were collected at the indicated time points for further analyses.
Generation of KSHV_WT and vIRF1_mutant recombinant virus

KSHV_WT and vIRF1_mutant constructs were previously described [16]. iSLK-RGB-BAC16 and iSLK-RGB-K9 mutant cells were used for the generation of KSHV_WT virus and vIRF1_mutant virus, which were induced by sodium butyrate and doxycycline as previously described [59]. By incubating $1 \times 10^7$ iSLK-RGB-BAC16 and iSLK-RGB-K9 mutant cells with Doxycycline (Dox) (1 $\mu$g/ml) and sodium butyrate (NaB) (1 mM) for 4–5 day, the supernatant was collected by ultracentrifugation (25, 000 g at 4˚C for 3 h) using SW32 Ti rotor (Beckman Coulter Inc, USA). The virus pellet was resuspended by DMEM supplemented with 8 $\mu$g/mL polybrene and then was subjected to infect $10^5$ indicated cells in 6 well plate at MOI of 3.

Expression profile analysis of circRNAs

Total RNAs were extracted from $1 \times 10^7$ cells using TRIzol reagent. The RNA quality (purity and concentration) was examined by NanoDrop ND-1000 (Thermo Fisher Scientific, USA). The ribosomal RNA was removed using Ribo zero rRNA removal Kit (Ribobio, China). After fragmenting to approximately 200 bp, 1$^{st}$ and 2$^{nd}$ strand cDNA was synthesized according to the instructions of NEBNext Ultra RNA Library Prep Kit for Illumina (NEB, USA) and then sequenced on HiSeq 3000 with 2 × 150 bp mode. Two algorithms, CIRI2 and CIRCexplorer2 were used to detect circRNAs. Reads were mapped to human reference genome GRCh37/ hg19 (http://genome.ucsc.edu/) by BWA-MEM or TopHat, respectively. If a circRNA can be detected by both methods, it will be considered as an identified cirRNA. Back-spliced junction reads identified in CIRI2 were combined and scaled to RPM (Reads Per Million mapped reads, bwamem mapping) to quantify every circRNAs. RNA-seq data have been submitted and can be accessed by GEO accession number GSE157615.

RT-PCR and qPCR

Total RNAs were transcribed into cDNA using HiScript III 1st Strand cDNA Synthesis Kit (+gDNA wiper) (Vazyme Biotech, China), according to manufacturer’s instructions. Target sequence of circARFGEF1 was amplified using 2$\times$ Phanta PCR Mix (Vazyme Biotech, China) following manufacturer’s instructions. RT-qPCR was employed to detect the target mRNAs or miR-125a-3p. GAPDH, Actin or U6 was served as the internal control to normalize the qPCR results. The PCR and RT-qPCR primers were listed in S3 Table.

RNA-seq analysis

The RNA-seq analysis was performed by Guangzhou RiboBio Co., Ltd. Briefly, RiboMinus Eukaryote Kit (Qiagen, CA) was used to remove ribosomal RNA; NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB, USA) was employed to prepare strand-specific RNA-seq libraries; the cDNA products were sequenced in a HiSeq 2000 system (Illumina, USA).

RNA preparation and treatment with RNase R or actinomycin D

Total RNAs were extracted from indicated cells using TRIzol RNA Isolation Reagents (Life Technologies, Grand Island, NY, USA), according to manufacturer’s instructions. Then 2 $\mu$g RNAs were incubated with 6 U RNase R (Epicenter Technologies, USA) for 20 min at 37˚C. For RNA degradation analysis, 2 mg/mL actinomycin D (Sigma-Aldrich, Germany) was added into cell cultured medium for indicated time.
Western blotting and antibodies

Western blotting was performed as previously described [60]. Cells were harvested by ice-cold RIPA lysis buffer, and an equal amount of protein was loaded into 10% SDS-PAGE gel. After electrophoresis, the gel was transferred into 0.45 μm polyvinylidene difluoride (PVDF) membrane. After blocking with 5% non-fat milk, the membranes were incubated with primary antibodies: anti-GLRX3 (ABclonal,[25]anti-Flag (Cell Signaling Technology, USA). Horseradish Peroxidase (HRP) conjugated secondary antibodies were used to detect the signals.

Immunohistochemistry (IHC)

The KS lesions and normal skin tissues were fixed in formalin. Tissues were embedded in paraffin and cut in a microtome to 5 μm. After deparaffinization, the antigen was retrieved using sodium citrate buffer. Then the tissues were incubated with GLRX3 antibody at 1:100 dilution (ABclonal, China). HRP-labeled Goat-Anti-Rabbit secondary antibody was used to detect the signals.

Dual-luciferase reporter assay

Dual-luciferase reporter assay was performed using the Dual-Luciferase Reporter (DLR) Assay System (Promega, USA), according to manufacturer’s instructions and our previous study [61–63]. Briefly, HEK293T cells were co-transfected with luciferase reporter plasmid and indicating gene plasmids for 48 h. The luminescence intensity of renilla and firefly luciferases was measured by a Luminometer.

RNA immunoprecipitation (RIP) assay

RIP assay was performed as previously described [16]. Cells were transduced with lentiviral circARFGEF1 and its control pLCDH. The EZ-Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Germany) and anti-Ago2 antibody (Millipore, Germany) were used to examine mRNA levels of circARFGEF1 and GLRX3 on Ago2-RISC, according to the manufacturer’s instructions.

RNA pull-down assay

RNA pull-down assay was performed as previously described by using biotin labeled miR-125a-3p probes [16]. Briefly, the cells were harvest by lysis buffer (Thermo Fisher Scientific, USA), and then incubated with streptavidin magnetic beads (Thermo Fisher Scientific, USA) and Biotin-labeled oligos. RT-qPCR was employed to detect the binding RNAs.

Mass spectrometry

Mass spectrometry analysis was performed as previously delineated [56, 60]. Briefly, proteins were reduced, alkylated, and digested with trypsin. The resulting peptides were labeled with isobaric tandem mass tags (TMT 6-plex; Thermo Fisher Scientific Inc., San Jose, CA), mixed, and fractionated by strongcation exchange chromatography. Peptide digests were analyzed by nanoscale reversed phase liquid chromatography (Easy-nLC, Thermo Fisher Scientific Inc.) coupled online with an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific Inc.). Spectra were searched using Maxquant (version 1.2.2.5), and results were filtered to 1% FDR at the unique peptide level using the COM-PASS software suite.
Transwell migration and Matrigel invasion assays

Transwell migration and Matrigel invasion were performed as previously described [57,64]. Briefly, 1 × 10^5 pri-HUVECs were seeded into 8 µm chambers (8-µm-pore polyethylene terephthalate membrane filter, Merck Millipore, Darmstadt, Germany) with or without matrigel coated, and were harvested 6 or 12 h after incubation. The migrated cells were fixed, stained, photographed and calculated by counting stained cells in a double-blinded manner by two observers.

Plate colony formation assay

To evaluate the ability of cell proliferation, the plate colony formation assay was performed as previously described [58]. Briefly, cells (about 2 × 10^3) were seeded in each well of 12-well plates with complete medium. Cultures were supplemented with complete medium per week. Cells were then fixed in methanol/glacial acetic acid (7:1), washed with water and stained with 0.5% crystal violet. Colonies were scored 14–21 days after seeding the cells.

Matrigel plug assay for angiogenesis in nude mice

Matrigel plug assay for angiogenesis in nude mice was performed as previously described [65–67]. Briefly, 3–4-week old male athymic BALB/c nu/nu mice were purchased from the Charles River laboratories and maintained under pathogen-free conditions. The mice experimental protocols were approved by Nanjing Medical University Experimental Animal Welfare Ethics Committee. The treated cells were harvested at subconfluence, washed with phosphate-buffered saline (PBS) and resuspended in serum-free medium. Cell aliquots (0.2 ml) were mixed with 0.4 ml of High Concentration Matrigel (BD Biosciences), and the mixture was immediately injected subcutaneously (s.c.) into the left flanks of nude mice. At day 10 after the injection, the mice were sacrificed, and the Matrigel plugs were removed from the mice. Small pieces of tissue were cut out and weighed, which were processed using the Drabkin’s reagent kit (Sigma–Aldrich, St Louis, MO, USA) with spectrophotometric analysis at 540 nm, followed by calculation of hemoglobin content based on the standard curve obtained.

Chromosome immunoprecipitation (ChIP)

ChIP assay was performed following the manufacturer’s instructions. Briefly, the anti-Flag and Lef1 antibodies immunoprecipitated DNAs were obtained by eluting the magnetic beads with ChIP elution buffer, and were purified for analysis using the circARFGEF1 promoter-specific primers through RT-qPCR. The sequences of circARFGEF1 promoter primers were provided in S2 Table.

Statistics

All data were presented with mean ± SD except the IHC results were presented with mean ± SEM. All experiments were performed at least three times, unless otherwise stated. The results were analyzed by Student’s t test. ANOVA followed by a pairwise test was used for multiple comparisons when examine more than 2 conditions. We consider values * P < 0.05, ** P < 0.01, and *** P < 0.001 significant.

Supporting information

S1 Fig. Determination of transduction efficiency of lentivirus-mediated vIRF1 in endothelial cells. qPCR results showing vIRF1 mRNA expression in EA.hy926 cells infected with KSHV (3 MOI) or transduced with different MOI of lentiviral vIRF1. The level of vIRF1 mRNA in KSHV infected cells was set as “1” for comparison. The quantified results represent the mean ± SD. (TIF)
S2 Fig. The primer location of pre-mRNA and mature mRNA of ARFGEF1. The red lines indicate the locations of forward and reverse primers for pre-mRNA of ARFGEF1, and the blues ones indicate the locations of primers for mature mRNA of ARFGEF1. (TIF)

S3 Fig. Neither KSHV infection nor ectopic expression of vIRF1 affects ARFGEF1 protein expression. (A). ARFGEF1 was detected after ectopic expression of vIRF1 in EA.hy926 cells via Western blotting. (B). ARFGEF1 was examined after KSHV (3 MOI) infection in EA.hy926 cells via Western blotting. (TIF)

S4 Fig. Overexpression of circARFGEF1 does not affect mRNA level of its parental gene ARFGEF1. (A). qPCR results showing circARFGEF1 expression in EA.hy926 cells infected with KSHV or transduced with different MOI of lentiviral circARFGEF1. The level of circARFGEF1 in KSHV cells was set as “1” for comparison. (B). qPCR results of circARFGEF1 and mRNA of its parental gene ARFGEF1 in EA.hy926 cells transduced with lentiviral circARFGEF1 at 1 or 4 MOI and its control pLCDH. Data were shown as mean ± SD. *** P < 0.001, Student’s t-test. n.s, not significant. (TIF)

S5 Fig. Knockdown of circARFGEF1 does not affect mRNA level of its parental gene ARFGEF1. (A). circARFGEF1 was silenced by lentivirus-mediated two shRNAs targeting circARFGEF1 and the knockdown efficiency of circARFGEF1 was measured by qPCR. (B). circARFGEF1 and mRNA level of its parental gene ARFGEF1 in EA.hy926 cells transduced with lentivirus-mediated shRNAs mix targeting circARFGEF1 or the control mpCDH. Data were shown as mean ± SD. * P < 0.05; *** P < 0.001, Student’s t-test. n.s, not significant. (TIF)

S6 Fig. The representative images of vIRF1-induced cell motility with knockdown of circARFGEF1. Lentiviral vIRF1 transduced pri-HUVECs were further transduced with a mixture of shRNAs targeting circARFGEF1 (shcircARFGEF1 mix), and were subjected to Transwell migration and invasion assays described in the “Materials and methods” section. The migrated and invaded cells were counted at 6 h and 12 h post seeding. Representational photographs of migration and invasion were exhibited (original magnification, ×100). Quantification of Transwell migration and invasion assay was described in Fig 3B and 3C. (TIF)

S7 Fig. The inhibitory cell colony formation by knockdown of circARFGEF1 is reversed by overexpression of circARFGEF1. EA.hy926 cells were transduced with lentivirus-mediated shcircARFGEF1 mix targeting circARFGEF1, and further transduced with lentivirus-mediated overexpression of circARFGEF1. Then cells were subjected to cell plate colony formation, which was fully described in “Materials and Methods” section. * P < 0.05, Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparisons test. (TIF)

S8 Fig. miR-125a-3p inhibits GLRX3 protein expression in a dose-dependent manner. GLRX3 protein expression in EA.hy926 cells transfected with increasing amounts of miR-125a-3p mimic (10, 20 and 50 nM) or its control (Neg. Ctrl.) for 48 h was quantified in Fig 6F. The difference of GLRX3 reduction was analyzed for three independent experiments. *** P < 0.001, Student’s t-test. (TIF)
S9 Fig. Knock down of GLRX3 by shRNAs. Western blotting was performed with the indicated antibodies in EA.hy926 cells transduced with lentiviruses containing shRNA 1 and 2, and a mixture of the two shRNAs targeting GLRX3 or the control mpCDH. Experiments were independently repeated three times with similar results. Results shown were from a representative experiment.

(TIF)

S10 Fig. The representative images of vIRF1-induced cell motility, plate colony formation and in vivo angiogenesis with knockdown of GLRX3. (A). GLRX3 was interfered by two different shRNAs in vIRF1 transduced pri-HUVECs. Cells were subjected to Transwell migration and invasion assay described in the "Materials and methods" section. The migrated and invaded cells were counted at 6 h and 12 h post seeding. Representational photographs of migration and invasion were exhibited (original magnification, ×100). Quantification of Transwell migration and invasion assay was described in Fig 7H and 7I. (B). Plate colony formation assay of EA.hy926 cells treated as in (A) was performed as described in the "Materials and methods" section. Representational photographs of plate colony were exhibited. Quantification of plate colony formation assay was described in Fig 7J. (C). The mixture containing high concentration Matrigel and EA.hy926 cells treated as in (A) was injected into nude mice. The details were shown in the "Materials and methods" section. Representational photographs of plugs were exhibited. Scar bars, 1 cm. Quantification of hemoglobin in plug tissues was described in Fig 7K.

(TIF)

S11 Fig. The representative images of KSHV-induced plate colony formation with knockdown of circARFGEF1 or GLRX3. (A). Plate colony formation analysis of EA.hy926 cells treated with PBS (PBS), infected with KSHV wild type virus (3 MOI) or transduced with lentivirus-mediated shcircARFGEF1 sequences targeting circARFGEF1. Plate colony formation assay was performed as described in the "Materials and methods" section. Quantification of plate colony formation assay was described in Fig 8D. (B). Plate colony formation analysis of EA.hy926 cells treated with PBS (PBS), infected with KSHV wild type virus (3 MOI) or transduced with lentivirus-mediated shGLRX3 targeting GLRX3. Plate colony formation assay was performed as described in the "Materials and methods" section. Quantification of plate colony formation assay was described in Fig 8G.

(TIF)

S1 Table. The cellular proteins dysregulated >1.5 folds in HUVECs expressing vIRF1. All dysregulated >1.5 folds proteins in HUVECs expressing vIRF1 were listed in this table including previously published ones (Li W et al. PLoS Pathog. 2019 Jan 30;15(1):e1007578).

(XLSX)

S2 Table. The sequences of the shRNAs.

(DOCX)

S3 Table. The sequences of specific primers of RT-qPCR.

(DOCX)

Acknowledgments

We are grateful to members from Dr. Lu laboratory for performing some preliminary experiments and providing useful information and helpful discussion. We thank Dr. Gary Hayward
of the Viral Oncology Program, The Johns Hopkins School of Medicine and Dr. Young Bong Choi of Johns Hopkins University School of Medicine for providing the polyclonal rabbit anti-vIRF1 antibody and information related to the source of vIRF1 antibody, respectively.

Author Contributions

Conceptualization: Weifei Fan, Chun Lu.

Data curation: Weifei Fan, Xiangya Ding, Chun Lu.

Formal analysis: Shuihong Yao, Xuemei Jia, Weifei Fan, Xiangya Ding, Shou-Jiang Gao, Chun Lu.

Funding acquisition: Shuihong Yao, Xiangya Ding, Shou-Jiang Gao, Chun Lu.

Investigation: Shuihong Yao, Fei Wang, Liuxue Sheng, Pengxia Song, Yanhui Cao, Hongjuan Shi, Xiangya Ding.

Methodology: Shuihong Yao, Fei Wang, Liuxue Sheng, Pengxia Song, Yanhui Cao, Hongjuan Shi, Xiangya Ding.

Project administration: Weifei Fan, Xiangya Ding, Chun Lu.

Resources: Xuemei Jia, Weifei Fan.

Software: Liuxue Sheng, Weifei Fan, Xiangya Ding.

Supervision: Chun Lu.

Validation: Weifei Fan, Xiangya Ding, Chun Lu.

Visualization: Xiangya Ding, Chun Lu.

Writing – original draft: Shuihong Yao, Xuemei Jia, Weifei Fan, Xiangya Ding.

Writing – review & editing: Shuihong Yao, Xuemei Jia, Weifei Fan, Xiangya Ding, Shou-Jiang Gao, Chun Lu.

References

1. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer. 2002; 2(5):373–82. Epub 2002/06/05. https://doi.org/10.1038/nrc797 PMID: 12044013.

2. Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008; 59(2):179–206; quiz 7–8. Epub 2008/07/22. https://doi.org/10.1016/j.jaad.2008.05.001 PMID: 18638627.

3. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994; 266(5192):1865–9. Epub 1994/12/16. https://doi.org/10.1126/science.7997879 PMID: 7997879.

4. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019; 5(1):9. Epub 2019/02/02. https://doi.org/10.1038/s41572-019-0060-9 PMID: 30705286.

5. Renne R, Zhong W, Hendriker B, McGrath M, Abbey N, Kedes D, et al. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996; 2(3):342–6. Epub 1996/03/01. https://doi.org/10.1038/nm0396-342 PMID: 8612236.

6. Zheng ZM. Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci. 2010; 6(7):730–55. Epub 2010/12/15. https://doi.org/10.7150/ijbs.6.730 PMID: 21152115; PubMed Central PMCID: PMC2989850.

7. Offermann MK. Kaposi sarcoma herpesvirus-encoded interferon regulator factors. Curr Top Microbiol Immunol. 2007; 312:185–209. Epub 2006/11/09. https://doi.org/10.1007/978-3-540-34344-6_7 PMID: 17089798.

8. Burysek L, Yeow WS, Lubyova B, Kellum M, Schafer SL, Huang YQ, et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular
interferon regulatory factors and p300. J Virol. 1999; 73(9):7334–42. Epub 1999/08/10. https://doi.org/10.1128/JVI.73.9.7334-7342.1999 PMID: 10438822; PubMed Central PMCID: PMC104259.

9. Li W, Wang Q, Qi X, Lu H, Chen Y, Shi J, et al. An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82. Cell Death Differ. 2020. Epub 2020/06/20. https://doi.org/10.1038/s41418-020-0578-0 PMID: 32555380.

10. Dittmer DP. Transcription profile of Kaposi’s sarcoma-associated herpesvirus in primary Kaposi’s sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 2003; 63(9):2010–5. Epub 2003/05/03. PMID: 12727810.

11. Zimring JC, Goodbourn S, Offermann MK. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol. 1998; 72(1):701–7. Epub 1998/01/07. https://doi.org/10.1128/JVI.72.1.701-707.1998 PMID: 9420276; PubMed Central PMCID: PMC109425.

12. Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene. 1997; 16(15):1979–85. Epub 1997/11/19. https://doi.org/10.1038/sj.ong.1210571 PMID: 9365244.

13. Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalk TF, et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol. 2006; 80(5):2257–66. Epub 2006/02/14. https://doi.org/10.1128/JVI.80.5.2257-2266.2006 PMID: 16474139; PubMed Central PMCID: PMC1395370.

14. Seo T, Park J, Lee D, Hwang SG, Choe J. Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol. 2001; 75(13):6193–8. Epub 2001/06/08. https://doi.org/10.1128/JVI.75.13.6193-6198.2001 PMID: 11390621; PubMed Central PMCID: PMC114335.

15. Vo MT, Smith BJ, Nicholas J, Choi YB. Activation of NIX-mediated mitophagy by an interferon regulatory factor homologue of human herpesvirus. Nat Commun. 2019; 10(1):3203. https://doi.org/10.1038/s41467-019-11164-2 PMID: 31324791; PubMed Central PMCID: PMC6492096.

16. Li W, Wang Q, Feng Q, Wang F, Yan Q, Gao SJ, et al. Oncogenic KSHV-encoded interferon regulatory factor upregulates HMGB2 and CMPK1 expression to promote cell invasion by disrupting a complex lncRNA-OIP5-AS1/miR-218-5p network. PLoS Pathog. 2018; 15(1):e1007578. Epub 2018/01/31. https://doi.org/10.1371/journal.ppat.1007578 PMID: 30699189; PubMed Central PMCID: PMC6370251.

17. Li W, Wang F, Shi J, Feng Q, Chen Y, Qi X, et al. Sperm associated antigen 9 promotes oncogenic KSHV-encoded interferon regulatory factor-induced cellular transformation and angiogenesis by activating the JNK/VEGFA pathway. PLoS Pathog. 2020; 16(8):e1008730. Epub 2020/08/11. https://doi.org/10.1371/journal.ppat.1008730 PMID: 32776977; PubMed Central PMCID: PMC7446834.

18. Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014; 20(12):1829–42. Epub 2014/11/19. https://doi.org/10.1261/rna.047126.114 PMID: 25404635; PubMed Central PMCID: PMC4238349.

19. Menczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495(7441):333–8. Epub 2013/03/01. https://doi.org/10.1038/nature11928 PMID: 23446348.

20. Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. PLoS Genet. 2013; 9(9):e1003777. Epub 2013/09/17. https://doi.org/10.1371/journal.pgen.1003777 PMID: 24039610; PubMed Central PMCID: PMC3764148.

21. Wang PL, Bao Y, Yee MC, Barrett SP, Hogan GJ, Olsen MN, et al. Circular RNA is expressed across the eukaryotic tree of life. PLoS One. 2014; 9(6):e90859. Epub 2014/03/13. https://doi.org/10.1371/journal.pone.0090859 PMID: 24609083; PubMed Central PMCID: PMC3946582.

22. Kristensen LS, Andersen MS, Stagsted LVV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20(11):675–91. Epub 2019/08/10. https://doi.org/10.1038/s41576-019-0158-7 PMID: 31395983.

23. Toptan T, Abere B, Nalesnik MA, Swerdlow SH, Ranganathan S, Lee N, et al. Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A. 2018; 115(37):E8737–E45. Epub 2018/08/29. https://doi.org/10.1073/pnas.1811728115 PMID: 30150410; PubMed Central PMCID: PMC6140489.

24. Tagawa T, Gao S, Koparde VN, Gonzalez M, Spouge JL, Serquina AP, et al. Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. Proc Natl Acad Sci U S A. 2018; 115(50):12805–10. Epub 2018/11/21. https://doi.org/10.1073/pnas.1816183115 PMID: 30455306; PubMed Central PMCID: PMC6294913.

25. Abere B, Li J, Zhou H, Toptan T, Moore PS, Chang Y. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded circRNAs Are Expressed in Infected Tumor Tissues and Are Incorporated into Virions. mBio.
26. Ungerleider NA, Jain V, Wang Y, Maness NJ, Blair RV, Alvarez X, et al. Comparative Analysis of Gammaherpesvirus Circular RNA Repertoires: Conserved and Unique Viral Circular RNAs. J Virol. 2019; 93(6). Epub 2018/12/21. https://doi.org/10.1128/JVI.01952-18 PMID: 30567979; PubMed Central PMCID: PMC6401440.

27. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495(7441):384–8. Epub 2013/03/01. https://doi.org/10.1038/nature11993 PMID: 23446346.

28. Huang W, Yang Y, Wu J, Niu Y, Yao Y, Zhang J, et al. Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-beta signalling. Cell Death Differ. 2019. Epub 2019/11/16. https://doi.org/10.1038/s41418-019-0455-x PMID: 31728016.

29. Patop IL, Wust S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019; 38(16):e100836. Epub 2019/07/26. https://doi.org/10.15252/embj.2018100836 PMID: 31343080; PubMed Central PMCID: PMC6694216.

30. Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol. 2008; 9(1):22–32. Epub 2007/12/13. https://doi.org/10.1038/nrm2321 PMID: 18073770.

31. Patop IL, Wust S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019; 38(16):e100836. Epub 2019/07/26. https://doi.org/10.15252/embj.2018100836 PMID: 31343080; PubMed Central PMCID: PMC6694216.

32. Pozharskaya VP, Weakland LL, Zimring JC, Krug LT, Unger ER, Neisch A, et al. Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J Virol. 2004; 78(12):6621–35. https://doi.org/10.1128/JVI.78.12.6621-6635.2004 PMID: 15163753.

33. Chioo CJ, Poole LJ, Kim PS, Ciufio DM, Cannon JS, ap Rhys CM, et al. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J Virol. 2002; 76(7):3421–39. Epub 2002/03/09. https://doi.org/10.1128/JVI.76.7.3421-3439.2002 PMID: 11884567; PubMed Central PMCID: PMC136009.

34. Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology. 2000; 269(2):335–44. Epub 2001/02/07. https://doi.org/10.1006/viro.2000.0196 PMID: 10753712.

35. Parravicini C, Chandran B, Corbellino M, Berti E, Pauli M, Moore PS, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000; 156(3):743–9. Epub 2000/03/07. https://doi.org/10.1016/S0002-9440(10)64940-1 PMID: 10702398; PubMed Central PMCID: PMC1876837.

36. Staskus KA, Zhong W, Gebhardt H, Herndier B, Wang H, Renne R, et al. Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997; 71(1):715–9. Epub 1997/01/01. https://doi.org/10.1128/JVI.71.1.715-719.1997 PMID: 8985403; PubMed Central PMCID: PMC191104.

37. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A. 1996; 93(25):14862–7. Epub 1996/12/10. https://doi.org/10.1073/pnas.93.25.14862 PMID: 8962146; PubMed Central PMCID: PMC26227.

38. Hew K, Dahlroth SL, Venkatachalam R, Nasertorabi F, Lim BT, Cornvik T, et al. The crystal structure of the DNA-binding domain of vIRF-1 from the oncogenic KSHV reveals a conserved fold for DNA binding and reinforces its role as a transcription factor. Nucleic acids research. 2013; 41(7):4295–306. https://doi.org/10.1093/nar/gkt082 PMID: 23435230; PubMed Central PMCID: PMC3627575.

39. Park J, Lee MS, Yoo SM, Jeong KW, Lee D, Choe J, et al. Identification of the DNA sequence interacting with Kaposi’s sarcoma-associated herpesvirus viral interferon regulatory factor 1. J Virol. 2007; 81(22):12680–4. Epub 2007/09/15. JVI.00566-07 [pii] https://doi.org/10.1128/JVI.00566-07 PMID: 17855527.

40. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56(1):55–66. Epub 2014/09/23. https://doi.org/10.1016/j.molcel.2014.08.019 PMID: 25242144.

41. Shang Q, Yang Z, Jia R, Ge S. The novel roles of circRNAs in human cancer. Mol Cancer. 2019; 18(1):6. Epub 2019/01/11. https://doi.org/10.1186/s12943-018-0934-6 PMID: 30626395; PubMed Central PMCID: PMC6325800.
42. He J, Huang Z, He M, Liao J, Zhang Q, Wang S, et al. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas. Mol Cancer. 2020; 19(1):17. Epub 2020/01/30. https://doi.org/10.1186/s12943-019-1120-2 PMID: 31992303; PubMed Central PMCID: PMC6986105.

43. Liu S, Qiu J, He G, Liang Y, Wang L, Liu C, et al. LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression. J Cancer. 2019; 10(26):6649–59. Epub 2019/11/30. https://doi.org/10.7150/jca.29213 PMID: 31775993; PubMed Central PMCID: PMC6856878.

44. Hou P, Li H, Yong H, Chen F, Chu S, Zheng J, et al. PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. Angiogenesis. 2019; 22(4):507–19. Epub 2019/06/30. https://doi.org/10.1007/s10456-019-09675-2 PMID: 31254127.

45. Zhong Y, Jiang L, Long X, Zhou Y, Deng S, Lin H, et al. Clinical Significance And Integrative Analysis Of Kinesin Family Member 1B In Lung Adenocarcinoma. Onco Targets Ther. 2019; 12:9249–64. Epub 2019/12/07. https://doi.org/10.2147/OTT.S27438 PMID: 31807007; PubMed Central PMCID: PMC6843202.

46. Cao Y, Shen T, Zhang C, Zhang QH, Zhang ZQ. MiR-125a-5p inhibits EMT of ovarian cancer cells by regulating TAZ/EGFR signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(19):8249–56. Epub 2019/10/28. https://doi.org/10.26355/eurrev_201910_19134 PMID: 31646555.

47. Zeybek A, Oz N, Kalemci S, Edgunlu T, Kiziltug MT, Tosun K, et al. Diagnostic Value of miR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma. Curr Med Res Opin. 2019; 35(3):469–75. Epub 2019/03/15. https://doi.org/10.1016/j.cmr.2019.03.009 PMID: 30868951.

48. de la Mata M, Gaidatzis D, Vitanescu M, Stadler MB, Wentzel C, Schiefele P, et al. Potent degradation of neuronal miRNAs induced by highly complementary targets. EMBO Rep. 2015; 16(4):500–11. Epub 2015/03/01. https://doi.org/10.15252/embr.201540078 PMID: 25724380; PubMed Central PMCID: PMC4388616.

49. Li W, Yan Q, Ding X, Shen C, Hu M, Zhu Y, et al. LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatic carcinoma progression. J Cancer. 2019; 10(2):626–36. Epub 2019/07/23. https://doi.org/10.7150/jca.29213 PMID: 31775993; PubMed Central PMCID: PMC6856878.
59. Bruloius KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, et al. Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol. 2012; 86(18):9708–20. https://doi.org/10.1128/JVI.01019-12 PMID: 22740391; PubMed Central PMCID: PMC3446615.

60. Li W, Hu M, Wang C, Lu H, Chen F, Xu J, et al. A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling. Oncogene. 2017; 36(38):5407–20. https://doi.org/10.1038/onc.2017.139 PMID: 28534512; PubMed Central PMCID: PMC6008636.

61. Yan Q, Ma X, Shen C, Cao X, Feng N, Qin D, et al. Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258. J Virol. 2014; 88(9):4987–5000. Epub 2014/02/21. https://doi.org/10.1128/JVI.00025-14 PMID: 24554664; PubMed Central PMCID: PMC3993842.

62. Yan Q, Shen C, Qin J, Li W, Hu M, Lu H, et al. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-kappaB Signaling. J Virol. 2016; 90(19):8739–53. https://doi.org/10.1128/JVI.00797-16 PMID: 27440900; PubMed Central PMCID: PMC5021437.

63. Yan Q, Zhao R, Shen C, Wang F, Li W, Gao SJ, et al. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi’s Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-kappaB-Signaling Axis. J Virol. 2018; 92(18). https://doi.org/10.1128/JVI.00025-18 PMID: 29976660; PubMed Central PMCID: PMC6146700.

64. Ding X, Xu J, Wang C, Xu J, Gao SJ, Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 2019; 26(10):1970–86. Epub 2019/01/24. https://doi.org/10.1038/s41418-018-0242-0 PMID: 30670829; PubMed Central PMCID: PMC6748093.

65. Yao S, Hu M, Hao T, Li W, Xue X, Xue M, et al. MiRNA-891a-5p mediates HIV-1 Tat and KSHV Orf-K1 synergistic induction of angiogenesis by activating NF-kappaB signaling. Nucleic acids research. 2015; 43 (19):9362–78. https://doi.org/10.1093/nar/gkv988 PMID: 26446687; PubMed Central PMCID: PMC4627096.

66. Ding X, Jia X, Wang C, Xu J, Gao SJ, Lu C. A DHX9-IncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 2019; 26(9):1750–65. https://doi.org/10.1038/s41418-018-0242-0 PMID: 30518908; PubMed Central PMCID: PMC6748089.

67. Zhu X, Guo Y, Yao S, Yan Q, Xue M, Hao T, et al. Synergy between Kaposi’s sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway. Oncogene. 2014; 33(15):1986–96. https://doi.org/10.1038/onc.2013.136 PMID: 23604117.